ArticleThe Journal of biological chemistry2026
PA14 domain of glycosyltransferase B4GALNT3 is a lectin that binds to sulfated glycan ligands.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mammalian proteins are decorated with a variety of glycans, providing proteins with enormous functional diversity. GalNAcβ1-4GlcNAc (LacdiNAc or LDN), a unique sub-terminal glycan structure regulating the half-life of circulating glycoproteins, is biosynthesized by the dedicated glycosyltransferases, B4GALNT3 and B4GALNT4. We recently reported that B4GALNT3 contains a unique non-catalytic PA14 domain that is necessary for the enzyme activity, while the precise function of PA14 is unclear. Here we show that PA14 in B4GALNT3 is a lectin domain required for the activity of B4GALNT3 toward glycoprotein substrates. Glycan microarray experiments, together with surface plasmon resonance and molecular dynamics simulations, demonstrated the specific binding between the PA14 domain of B4GALNT3 and sulfated glycan ligands, such as Gal[6S]β1-4GlcNAc[6S]. Both addition of the sulfated disaccharide ligands and point-mutation at the putative sugar binding site in the PA14 domain inhibited the in vitro activity of B4GALNT3 particularly toward glycoprotein substrates. These data suggest that sulfated glycans negatively regulate the PA14-dependent catalytic activity of B4GALNT3 toward glycoproteins. Suppression of cellular glycan sulfation by knocking out the Golgi transporters for sulfation donor PAPS, SLC35B2, and SLC35B3, likely resulted in the enhanced biosynthesis of LDN by B4GALNT3 in cells. Moreover, overexpression of CHST8, which catalyzes sulfation of LDN, seemed to reduce B4GALNT3 activity in cells, suggesting negative feedback regulation of B4GALNT3 by the sulfated product. These findings indicate that recognition of sulfated glycan ligands by its PA14 domain negatively regulates B4GALNT3 activity, highlighting a novel regulation mechanism for LDN synthesis mediated by a lectin domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.